Shire Expands Scholarship Program for Individuals with ADHD
The second year of the Shire ADHD Scholarship Program will award fifty (50) scholarships to individuals with ADHD
Philadelphia, PA, US – October 20, 2011 – Shire, a global specialty biopharmaceutical company, has expanded its ADHD Scholarship Program. The program is for individuals in the United States diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) who are pursuing higher education at a college, vocational school or technical school. Fifty winners will be selected in 2012, twice as many as in the first year.
The Shire ADHD Scholarship includes a $2,000 monetary award and offers a prepaid year of ADHD coaching services provided by the HEdge FoundationH to assist with the transition to higher education. Fifty one-time scholarships will be awarded on June 12, 2012. The deadline to apply is March 30, 2012. For information, including eligibility requirements and scholarship application, visit www.ShireADHDScholarship.com.
“The response to the Shire ADHD Scholarship Program in 2011 was tremendous, with hundreds of applications from inspiring students across the nation,” said Michael Yasick, Senior Vice President of Shire’s ADHD business. “There are thousands of high school seniors, college students, and adults going on to higher education who suffer from ADHD. We want to recognize the brave individuals who work hard to overcome the challenges of this life-altering condition, and help them continue their educational pursuits.”
Award recipients will be offered ADHD coaching from the Edge Foundation, which includes weekly sessions with specially trained ADHD coaches. The students set weekly goals and action plans to meet those goals and have e-mail and phone support from their coaches to help keep them on track. This support may be important for students transitioning to the higher education environment because they have more free time and less adult supervision.
The Edge Foundation is a Seattle-based nonprofit organization that offers support for students with ADHD. The Edge Foundation’s primary mission is to provide access to qualified, professional coaches for students with ADHD as part of their multi-modal treatment program. For more information on the Edge Foundation, please visit the company’s website: www.edgefoundation.org.
Shire’s ADHD Scholarship Program is part of Shire’s patient centric approach that offers support to patients, parents, advocates and others while providing care for people diagnosed with ADHD.
For further information please contact:
Media
Matthew Cabrey (mcabrey@shire.com)
Shire Pharmaceuticals
1-484-595-8248
Bev Volpe (bvolpe@simonpr.com)
Simon Public Relations Group
1-215-545-4715 Ext 24
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases, and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger, and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. For further information on Shire, please visit the Company’s website: www.shire.com.
“SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing, and commercialization of the Company’s Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company’s products; the Company’s ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company’s products; the Company’s ability to register, maintain, and enforce patents and other intellectual property rights relating to its products; the Company’s ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company’s filings with the Securities and Exchange Commission.
© 2011 Shire US Inc., Wayne, PA 19087
Please note: I reserve the right to delete comments that are offensive or off-topic.